MedTrace Logo

Outcomes of HCC (Hepatocellular Carcinoma) Patients Treated With TACE (Transarterial Chemoembolization) and Early, Not Early or Not at All Followed by Sorafenib

NCT01933945 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1676

Last updated 2018-11-06

No results posted yet for this study

Summary

This study will collect data of patients who are treated with TACE followed by sorafenib for hepatocellular carcinoma (HCC) or patients without Sorafenib after TACE. In contrast to a prior observational study on sorafenib (GIDEON study), where pre-treatment with TACE was documented retrospectively, this study will collect more detailed information about the TACE treatment and the status of a patient when treatment with sorafenib is started.

Conditions

  • Carcinoma, Hepatocellular

Interventions

PROCEDURE

TACE (transarterial chemoembolization)

First treatment for all patients included in the study

DRUG

Sorafenib (Nexavar, BAY43-9006)

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-28
Primary Completion
2017-07-22
Completion
2017-11-10

Countries

  • Austria
  • Brazil
  • Canada
  • China
  • Czechia
  • Denmark
  • Egypt
  • France
  • Greece
  • Hong Kong
  • Hungary
  • India
  • Indonesia
  • Israel
  • Japan
  • Kazakhstan
  • Mexico
  • Netherlands
  • Pakistan
  • Poland
  • Russia
  • Singapore
  • Slovakia
  • South Korea
  • Spain
  • Sweden
  • Switzerland
  • Taiwan
  • Thailand
  • Turkey (Türkiye)
  • Vietnam

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01933945 on ClinicalTrials.gov